XNASKTTAW
Market cap3mUSD
Jan 07, Last price
0.03USD
1D
38.40%
1Q
37.69%
IPO
-96.03%
Name
Pasithea Therapeutics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-16m
L+22.25%
CFO
0k
P
Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 487 3,130.37% | |||
Cost of revenue | 15,979 | 15,303 | ||
Unusual Expense (Income) | ||||
NOPBT | (15,979) | (14,816) | ||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | (15,979) | (14,816) | ||
Net income | (15,962) 22.25% | (13,056) 500.57% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | (3,726) | (3,206) | ||
BB yield | 41.05% | 19.79% | ||
| Debt | ||||
Debt current | 82 | 263 | ||
Long-term debt | 82 | 1,590 | ||
Deferred revenue | ||||
Other long-term liabilities | 84 | 141 | ||
Net debt | (16,168) | (31,293) | ||
| Cash flow | ||||
Cash from operating activities | (14,562) | |||
CAPEX | (34) | (2,139) | ||
Cash from investing activities | 399 | (2,062) | ||
Cash from financing activities | (3,726) | (3,206) | ||
FCF | (14,947) | (16,049) | ||
| Balance | ||||
Cash | 16,331 | 33,147 | ||
Long term investments | ||||
Excess cash | 16,331 | 33,123 | ||
Stockholders' equity | (35,323) | (19,340) | ||
Invested Capital | 58,888 | 62,905 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 1,227 | 1,262 | ||
Price | 7.40 -42.34% | 12.83 -63.75% | ||
Market cap | 9,077 -43.97% | 16,201 -60.22% | ||
EV | (7,091) | (15,092) | ||
EBITDA | (15,331) | (14,784) | ||
EV/EBITDA | 0.46 | 1.02 | ||
Interest | 102 | |||
Interest/NOPBT | ||||